This company is a Boston-based biopharmaceutical company developing immune-based approaches.
BITT has developed a platform for targeting the tumor necrosis factor receptor 2 (TNFR2) oncogene and the potent population of TNFR2 Tregs in the tumor microenvironment.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Mar 17, 2021 | Series A | $10M | 1 | BeiGene | — | Detail |